Figure 1
Ras-GRF2 interactions with Ras and Rho-family GTPases mediated by the Ras-GRF2 Cdc25 and DH domains. (a) Glutathione-S-transferase (GST) alone or linked to Ras, RhoA, Rac1 or Cdc42 were prepared in either their nucleotide-free (NF), GDP-bound (GDP) or GTPγS-bound (GTPγS) forms and analyzed for their interactions with FLAG-epitopetagged Ras-GRF2 (WT, top panels), and mutant versions lacking the DH domain (∆DH, middle panels) or Cdc25 domain (∆Cdc25, bottom panels). Incubations were performed in the presence (+) or absence (-) of cell lysate. (b) Ras GEF and Rac1 GEF activities associated with Ras-GRF2. Ras-GRF2-catalyzed release of unlabeled GDP and association of 32 P-labeled GTP with GST or the indicated GTPases during a 30 min incubation period. Values are means ± s.e.m. for four independent experiments. No GEF activity was detected with GST or anti-FLAG antibody immunoprecipitates from control 293 cells. response to an elevation in intracellular calcium [3, 4] . Analysis of activated GTP-bound Ras in cell lysates expressing Ras-GRF2 indicated that activation of Ras by Ras-GRF2 requires the Cdc25 domain, but can occur in the absence of the DH domain (Figure 2a ). Consistent with this, removal of the DH domain from Ras-GRF2 did not diminish its basal or calcium-stimulated activation of the MAP kinase ERK1 (Figure 2) . Deletion of the Cdc25 domain, or the IQ sequence, which is required for the CaM interaction [4] , impaired ERK1 activation by Ras-GRF2 in response to calcium ionophore treatment ( Figure 2 ). These results indicate that the Cdc25 domain, but not the DH domain, is involved in Ras-GRF2-mediated activation of Ras and ERK.
SAPK (also known as Jun N-terminal kinase or JNK) is a MAPK distinct from ERK, and is activated downstream of Rac1 and Cdc42 [1] . Activation of SAPK requires dual phosphorylation in its kinase domain [1] . In 293T cells transfected with a control vector, ionomycin treatment did not cause phosphorylation of SAPK, whereas the treatment of cells with anisomycin, a potent activator of the SAPK pathway, caused both p46 and p54 isoforms of SAPK to become reactive with antibodies specific for phosphorylated SAPK (Figure 3a) . Expression of Ras-GRF2, even in unstimulated cells, caused p54 SAPK to be phosphorylated to levels comparable to that seen with anisomycin treatment. Treatment of cells with ionomycin did not further increase SAPK phosphorylation, whereas SAPK phosphorylation was further increased in Ras-GRF2-expressing cells by treatment with anisomycin ( Figure 3a) . Measurement of substrate binding and SAPK activity in vitro indicated that the expression of Ras-GRF2 caused an elevation in basal SAPK activity approximately fivefold over that seen in unstimulated vector-transfected cells. Calcium ionophore treatment of cells expressing Ras-GRF2 caused an increase in SAPK activity 14-fold above that seen in the untreated control cells (Figure 3b) . SAPK activation by Ras-GRF2 was abolished in the ∆IQ mutant ( Figure 3b ) suggesting that both the Rac and Ras GEF activities of Ras-GRF2 are governed by its interaction with CaM. This effect is likely to be indirect as the ∆IQ mutant, or chelator-treated Ras-GRF2 that was not associated with CaM, displayed wild-type levels of Ras and Rac GEF activity in vitro (data not shown). The IQ-CaM interaction may therefore influence the interaction of Ras-GRF2 with its targets, possibly by affecting Ras-GRF2 subcellular localization. Ras-GRF2-mediated activation of SAPK is not simply a consequence of the activation of the Ras pathway, but rather occurs as a function of the Ras-GRF2 DH domain. The ∆DH mutant, which behaved like the wild-type protein with respect to ERK activation (see Figure 2) , was completely ineffective towards SAPK. The ∆Cdc25 protein, which is defective for Ras interaction and activation, retained some ability to activate the SAPK pathway, exhibiting a threefold activation of SAPK in unstimulated cells that was increased to approximately fivefold following ionomycin treatment. The diminished activation of SAPK caused by the deletion of the Cdc25 domain may reflect a contribution of this domain or of the activated Ras pathway on the ability of Ras-GRF2 to interact with Rac in vivo. The ∆Cdc25 protein, like the other variants described here and the wild-type protein, was found to be stably expressed in 293 cells, and deletion of the Cdc25 domain did not affect Ras-GRF2-associated in vitro Rac GEF activity or its domain structure as determined by partial proteolysis with trypsin (data not shown).
Ras and related GTPases harboring mutations at aminoacid position 17 (N17), or its equivalent, display impaired nucleotide interactions, and have been exploited as effective dominant-negative inhibitors of GEFs [5] [6] [7] . Ras-N17 and Rac-N17, when expressed individually, were effective inhibitors of both ERK and SAPK activation by Ras-GRF2 ( Figure 4 ). These results are consistent with the strong binding of the Ras-GRF2 Cdc25 and DH domains to nucleotide-free Ras and Rac, respectively (Figure 1) , and indicate that both the Cdc25 and DH domains are effectively inhibited when either one is engaged with an N17 protein. The ability of either dominant-negative protein to inhibit signaling by both of the GEF domains suggests that Ras-GRF2 is indeed the common target of both Ras-N17 and Rac-N17, and that only one of the GEF domains of Ras-GRF2 may function at a time. By virtue of its two GEF domains, Ras-GRF2 may be able to activate Ras and Rac in a coordinated fashion, and this may constitute a form of cross-talk between Ras and Rac signaling pathways.
Activation of Rac and membrane ruffling can occur downstream of Ras and involves phosphatidylinositol (PI) 3-kinase [8] , possibly by activating a Rac GEF activity associated with the Sos DH domain [9] . Ras-GRF2-mediated activation of SAPK was not inhibited by the PI 3-kinase inhibitor wortmannin (data not shown) suggesting that the ability of Ras-GRF2 to activate Rac and the SAPK pathway does not require activation of PI 3-kinase. Nevertheless, as has been suggested for other cases of wortmannin-resistant Rac activation [8] , it is possible that a wortmannin-resistant PI 3-kinase may provide a co-stimulatory signal to enable Ras-GRF2-mediated activation of Rac. Histogram indicating Ras-GRF2-mediated and Ca 2+ (ionomycin treatment)-induced SAPK activation that was dependent on the IQ and DH domains and was stimulated by calcium ionophore treatment (Ca 2+ ). Cells (293T) were co-transfected with plasmids as described in Figure 2 , but the ERK1 construct was substituted by one encoding HA-tagged SAPK. SAPK was isolated from lysates by association with GST-c-Jun, and these immobilized complexes were introduced into kinase reactions containing [γ-32 P]ATP. Quantification of SAPK expression, monitored by immunoblotting and chemiluminescence detection, and phosphorylation of gel-resolved GST-c-Jun, was performed using a phosphorimager. Mean values ± s.e.m. from three independent experiments are shown. Rac-N17, however, it remains possible that Ras-GRF2 affects SAPK by a Rac-independent mechanism.
Ras and Rac each interact with a distinct set of effector proteins and an overlapping set of exchange factors including, at least, Ras-GRF2 and Sos. Rac-mediated changes in the actin cytoskeleton, MAPK cascades, and transcription are important components of the cellular response to growth factors and other events that concomitantly cause activation of Ras [8, 11, 12] . Our results suggest that Ras-GRF2 is a bifunctional protein able to activate both Ras and Rac and thereby coordinate the signaling by otherwise distinct MAPK cascades. It remains to be determined whether Ras-GRF2 affects any of the other Ras and Rac effector pathways, and whether exchange factors in general function as determinants of effector protein-GTPase interactions.
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Figure 4
Activation of both ERK and SAPK by Ras-GRF2 is inhibited by dominant-negative forms of Ras and Rac1. (a) Co-expression of either Ras-N17 or Rac1-N17 with Ras-GRF2 and ERK1 by transient transfection of 293T cells inhibited basal and calcium-ionophoreinduced ERK1 activity. Ras-GRF2 expression was confirmed by immunoblotting with anti-FLAG antibody, and ERK1 activity determined by assessing MBP phosphorylation as described in the legend to Figure 2 . (b) Similarly, Ras-GRF2-mediated activation of SAPK, measured by immunoblotting with anti-pSAPK antibodies (as described in Figure 3 ), was also inhibited by co-expression of Ras-N17 or Rac1-N17 with Ras-GRF2 and HA-tagged SAPK. (c) Immunoblot analysis confirmed expression of Ras-N17 and Myc-tagged Rac1-N17 proteins. The Cdc25 and DH domains of Ras-GRF2 interact specifically with Ras and Rac, respectively (see Figure 1) . Assuming that the N17 derivatives retain this specificity for the different GEF domains of Ras-GRF2, these results indicate that when either one of the GEF domains is engaged with an inhibitor, the other GEF domain is unable to function. 
